US FDA · Draft guidance
FDA proposes guidance on responding to Form 483 observations
Official source date: · Source checked
The draft addresses manufacturers choosing to respond to observations after a drug CGMP inspection. Its audience includes domestic and foreign human and animal drug manufacturers regulated by CDER, CBER and CVM.
Who should review this?
Quality-unit leaders, inspection-response coordinators and regulatory affairs teams at drug manufacturers.
What it means for pharmaceutical teams
This announcement is about response guidance, not a report that a particular company received observations. Teams considering the draft should distinguish its proposed recommendations from existing obligations and the specific facts of their own inspection.
Practical review checklist
PharmaEdges reading prompts for your own applicability review:
- Read the draft for its intended audience and response scope.
- Compare the proposed approach with your inspection-response procedure and supporting evidence practices.
- Check FDA for a final version before citing the draft as current final guidance.
Official source and verification
Read the US FDA source (opens in a new tab)
This article summarises the linked official material. The context and checklist are PharmaEdges explanatory commentary, not additional regulatory requirements. The source publication date is separate from this article’s publication date.
For a correction, contact PharmaEdges with the article URL and supporting source. Read our news publishing policy.
Related fda intelligence
- FDA finalises guidance on postapproval biosimilar manufacturing changes
- FDA publishes final ICH E2B(R3) guidance for electronic safety reports
- FDA proposes updated principles for container closure quality
- FDA issues inspection programme for CDER-regulated biologics